Bicycle therapeutics announces poster presentations at the 2025 asco annual meeting

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 american society for clinical oncology (asco) annual meeting, taking place may 30-june 3 in chicago. poster presentation details: title: phase 1/2 duravelo-1 study: preliminary results of nectin.
BCYC Ratings Summary
BCYC Quant Ranking